High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release
oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times
daily for 2 weeks followed by 50 milligrams per kilogram twice daily for 2 weeks, will
resolve an acute flare of ileocecal Crohn's disease.